About this information
Search the summaries of completed Access to Information (ATI) requests to find information about ATI requests made to the Government of Canada after January 2020. If you find a summary of interest, you can request a copy of the records at no cost using the form below each summary. Requests made through this form are considered informal requests and are not subject to the same requirements as requests under the Access to Information Act (ATIA).
If you don’t find what you are looking for you can request additional government records under an institution’s control by contacting the institution’s Access to Information and Privacy Coordinator or by submitting a formal access to information request.
*All information provided will incorporate the necessary exemptions and exclusions as per the Access to Information Act and the Privacy Act.
Download datasets of the summaries of completed access to information requests.
Found 535 record(s)
Req # A-2022-001651
Health Canada is currently reviewing an Abbreviated New Drug Submission (ANDS) seeking approval of a product containing the medicinal ingredient desmopressin acetate which was accepted into review on or after December 1, 2022. Identify the Canadian…Organization: Health Canada
July 2023
Req # A-2022-001654
Health Canada is currently reviewing an Abbreviated New Drug Submission (ANDS) seeking approval of a product containing the medicinal ingredient desmopressin acetate which was accepted into review on or after December 1, 2022. Please provide the…Organization: Health Canada
July 2023
Req # A-2022-001655
Health Canada is currently reviewing an Abbreviated New Drug Submission (ANDS) seeking approval of a product containing the medicinal ingredient desmopressin acetate which was accepted into review on or after December 1, 2022. Provide: the month and…Organization: Health Canada
July 2023
Req # A-2023-000011
The initial cover letter indicating the brand name of the reference drug product and the dosage form of the generic drug in Health Canada’s list of “Generic Drug Submissions Under Review” dated 2023-03-24 for the medicinal ingredient Nitrofurantoin…Organization: Health Canada
July 2023
Req # A-2023-000014
The initial cover letter and any other document indicating the brand name of the reference drug product and the dosage form of the generic drug in Health Canada’s list of “Generic Drug Submissions Under Review” dated 2023-03-24 for the medicinal…Organization: Health Canada
July 2023
Req # A-2023-000037
The information the Medical Devices Directorate has on file for the Convivo System (Medical Device License No. 106067), Manufacturer CARL ZEISS MEDITEC AG as follows: Licensed indications for use of the Convivo System (Class II MDL 106067) and Copy…Organization: Health Canada
July 2023
Req # A-2023-000038
All information included in the submission and review of Natural Product Number (NPN) 80111110 BacoMind Children. Licence holder: Natural Remedies Private Limited, Date of Licensing: 06/30/21.Organization: Health Canada
July 2023
Req # A-2023-000054
On the 12 July 2022 under “illegal marketing of drugs and devices” a compliance letter had been sent to Boston C Canada Inc. A copy of this letter and any related material such as a follow up letter of actions.Organization: Health Canada
July 2023
Req # A-2023-000194
All current Health Canada approved labelling and currently approved intended use for: Licence No.: 98062 BTL-6000 SUPER INDUCTIVE SYSTEM ELITE.Organization: Health Canada
July 2023
Req # A-2023-000312
The National Microbiology Laboratory‘s report on BTNX‘s 200 samples.Organization: Health Canada
July 2023